Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spect… (NCT02814591) | Clinical Trial Compass
UnknownNot Applicable
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
245 participantsStarted 2011-10
Plain-language summary
In this study spatially offset Raman spectroscopy (SORS), which allows the collection of Raman spectra through turbid media, is being applied to collect Raman spectra of bone. The principal aim to find ways to use Raman spectroscopy to assess bone quality in vivo.
Who can participate
Age range0 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
INCLUSION CRITERIA
Cohort 1: 40 volunteers, free from bone disease:
* Participants must be free from bone disease and not have a family history of OI;
* Participants to be age and sex matched with OP participants may be recruited among individuals attending the RNOH Metabolic Unit for DXA scanning, who are shown to have normal bone density T score\> -2.5;
* No history of non-accidental fracture;
* No history of OA or clinical manifestations of disease;
* No clinical features of OI;
* Controls will be sex and age matched (within five years) to the disease cohort patients.
* Children and adults both required
Cohort 2: 40 patients with OI:
* Patients must have been clinically diagnosed with OI;
* Where possible participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database; if not from RNOH then diagnosis will be otherwise confirmed
Cohort 3: 40 patients with OA:
* Patients must have been clinically diagnosed with OA;
* Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database; if not from RNOH then diagnosis will be otherwise confirmed
Cohort 4: 40 patients with OI, receiving treatment with bisphosphonates:
* Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment;
* 20 Adults and 20 children
* Where possible participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database; if not from RNOH then diag…
What they're measuring
1
SORS Raman spectral fingerprint for bone disease types and changes over time
Timeframe: SORS Raman spectral features will be evaluated using a variety of multi-variate analytical tools e.g. BTEM at time zero and a repeat measure within a year.